Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
28.04. | Health misinformation: can pharma really have an impact? | ||
25.04. | Johnson & Johnson's Tremfya granted EC approval to treat ulcerative colitis in adults | ||
25.04. | Boehringer Ingelheim and Tessellate Bio enter oncology partnership worth over €500m | ||
25.04. | Ipsen's elafibranor shows promise in rare liver disease primary sclerosing cholangitis | ||
25.04. | The AI revolution in healthcare - unlocking a new era of medical innovation | ||
24.04. | Roche's Genentech enters $765m autoimmune disease partnership with Repertoire | ||
24.04. | Biogen's Skyclarys granted MHRA approval for rare movement disorder Friedreich's ataxia | ||
24.04. | Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer | ||
24.04. | DE&I - don't throw the baby out with the bathwater | ||
23.04. | Pfizer's Hympavzi granted MHRA approval to treat haemophilia A and B | ||
23.04. | BMS receives NICE recommendation for immunotherapy combination in colorectal cancer | ||
23.04. | AstraZeneca/Daiichi Sankyo's Enhertu shows promise in first-line HER2-positive breast cancer | ||
23.04. | Tackling the antibiotic resistance crisis | ||
22.04. | Unlock the Future of Patient Recruitment: Learnings from 15 Years of Innovation | ||
22.04. | Sanofi/Regeneron's Dupixent granted FDA approval for chronic spontaneous urticaria | ||
22.04. | GSK's Blenrep combinations approved by MHRA to treat multiple myeloma | ||
22.04. | FDA approves pre-filled syringe version of argenx's immune disorder drug Vyvgart | ||
22.04. | Coach Tolstoy: The surprising coaching lesson from Russian literature | ||
17.04. | GSK's five-in-one meningococcal vaccine recommended by CDC advisory committee | ||
17.04. | LEO Pharma and the Parker Institute join forces to advance dermatology research | ||
17.04. | FDA grants interchangeable designation to Celltrion's Humira biosimilar Yuflyma | ||
17.04. | The impact of multiple sclerosis on ageing patients | ||
16.04. | Shared decision-making in oncology - turning principles into practice | ||
16.04. | Biogen/Eisai's Alzheimer's disease drug Leqembi granted EC approval | ||
16.04. | Merck and Cyprumed enter oral peptide partnership worth over $493m |